Phase I NK510-PD-1 combination shows preliminary safety in nine lung cancer patients
A nine-patient phase I trial found that TIGIT-disrupted NK510 could be combined with PD-1 blockade without observed dose-limiting toxicities in ...
Tag: NK510
A nine-patient phase I trial found that TIGIT-disrupted NK510 could be combined with PD-1 blockade without observed dose-limiting toxicities in ...
